Your browser doesn't support javascript.
Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination.
Ogata, Shunsuke; Ishii, Yoshito; Asano, Keiichiro; Kobayashi, Erena; Kubota, Shun; Takahashi, Keita; Miyaji, Yosuke; Higashiyama, Yuichi; Joki, Hideto; Doi, Hiroshi; Koga, Michiaki; Takeuchi, Hideyuki; Tanaka, Fumiaki.
  • Ogata S; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Ishii Y; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Asano K; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Kobayashi E; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Kubota S; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Takahashi K; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Miyaji Y; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Higashiyama Y; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Joki H; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Doi H; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Koga M; Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Japan.
  • Takeuchi H; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
  • Tanaka F; Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
Intern Med ; 61(11): 1757-1760, 2022 Jun 01.
Article in English | MEDLINE | ID: covidwho-1951856
ABSTRACT
Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Guillain-Barre Syndrome / COVID-19 Type of study: Case report / Diagnostic study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Humans Language: English Journal: Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article Affiliation country: Internalmedicine.8967-21

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Guillain-Barre Syndrome / COVID-19 Type of study: Case report / Diagnostic study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Humans Language: English Journal: Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article Affiliation country: Internalmedicine.8967-21